ClearPoint Neuro Shares Fall 24% Following uniQure AMT-130 Trial Update
Clearpoint Neuro Inc CLPT
$11.77
▼ -23.12%
($-3.54)
⬇️ Below Yest. Low
Open
$12.63
Prev Close
$15.31
Day Range
$11.60 – $12.99
52W Range
$8.27 – $30.10
Market Cap
$359.03M
Beta
1.31
EPS (TTM)
$-1.18
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-07-03 |
| Shares Out. | 29,990,000 |
| Website | clearpointneuro.com/ ↗ |
| Phone | 13026587581 |
| Employees | 172 |
| Revenue | $10.9M |
| Gross Profit | $6.7M |
| Net Income | -$11.3M |
| Free Cash Flow | -$31.3M |
| Total Assets | $86.7M |
| Total Liabilities | $76.0M |
| Equity | $10.8M |
About Clearpoint Neuro Inc
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
Clearpoint Neuro Inc is a publicly traded company under the ticker symbol CLPT on the NASDAQ NMS - GLOBAL MARKET, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-09-01)